Bayer Stock News

Bayer Aktiengesellschaft remains deeply undervalued despite ongoing business struggles and litigation headwinds, with significant upside potential if challenges are resolved. Bayer's Q2 '25 results were mediocre, but the company raised 2025 guidance and is making progress on litigation settlements, aiming for containment by the end of 2026. The turnaround strategy includes workforce reductions,...

ORLANDO, Fla.--(BUSINESS WIRE)-- #BiotechNews--Hesperos, Inc. (Hesperos), a global leader focused on improving preclinical drug development, food, cosmetic, and chemical testing with its Human-on-a-Chip® (HoaC) single- and multi-organ systems platform, is pleased to announce the publication of a new peer-reviewed study, developed in collaboration with Bayer Consumer Health. The study introduces...

ST. LOUIS--(BUSINESS WIRE)--Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm in the United States. This recognition places Cornfed Farms as one of 16 farms around the globe, highlighted by Bayer as committed to advancing regenerative agriculture pra...

10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign 10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bayer Canada is pleased to announce a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL® 30 mg tablets1 in Canada. This strategic collaboration took effect on September 3, 2025. “We are excited to partner with Mint Pharmaceuticals Inc., a company known for its commitment to quality and customer service,” said Viktoria Friedr...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)'s Annual Scientific Meeting in Minneapolis, Minnesota, September 26-29, 2025. In July 2025, the U.S. Food and Drug Administration (FDA) approved a new indication for KERENDIA to treat adult p...

Bayer's pioneering cell and gene therapies for Parkinson's disease are at the forefront of an exciting but risky test of CEO Bill Anderson's development credentials as patent expiries on blockbuster drugs threaten the group's long-term growth projects.

Bayer Chief Executive Bill Anderson said the company is making "remarkable progress" in overcoming longstanding challenges, including a weak drug development pipeline, after an internal management overhaul.